300347 Stock Overview
Provides contract research organization services in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Hangzhou Tigermed Consulting Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥51.18 |
| 52 Week High | CN¥73.19 |
| 52 Week Low | CN¥36.12 |
| Beta | 0.66 |
| 11 Month Change | 0.65% |
| 3 Month Change | -5.10% |
| 1 Year Change | -23.13% |
| 33 Year Change | -60.63% |
| 5 Year Change | -14.27% |
| Change since IPO | 1,128.32% |
Recent News & Updates
Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Share Price Could Signal Some Risk
Aug 21
Hangzhou Tigermed Consulting (SZSE:300347) Is Increasing Its Dividend To CN¥0.568
Jul 12Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?
Jun 26Recent updates
Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Share Price Could Signal Some Risk
Aug 21Hangzhou Tigermed Consulting (SZSE:300347) Is Increasing Its Dividend To CN¥0.568
Jul 12Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?
Jun 26An Intrinsic Calculation For Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Suggests It's 35% Undervalued
Jun 07Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 28Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Apr 08Hangzhou Tigermed Consulting's (SZSE:300347) Profits Appear To Have Quality Issues
Apr 04Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models
Apr 01Shareholder Returns
| 300347 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 7.2% | -1.0% | -0.6% |
| 1Y | -23.1% | -46.0% | -13.8% |
Return vs Industry: 300347 exceeded the CN Life Sciences industry which returned -46% over the past year.
Return vs Market: 300347 underperformed the CN Market which returned -13.8% over the past year.
Price Volatility
| 300347 volatility | |
|---|---|
| 300347 Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300347 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300347's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9,701 | Xiaochun Cao | www.tigermedgrp.com |
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary
| 300347 fundamental statistics | |
|---|---|
| Market cap | CN¥41.13b |
| Earnings (TTM) | CN¥1.13b |
| Revenue (TTM) | CN¥7.03b |
39.0x
P/E Ratio6.3x
P/S RatioIs 300347 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300347 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.03b |
| Cost of Revenue | CN¥4.33b |
| Gross Profit | CN¥2.70b |
| Other Expenses | CN¥1.57b |
| Earnings | CN¥1.13b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.31 |
| Gross Margin | 38.36% |
| Net Profit Margin | 16.06% |
| Debt/Equity Ratio | 15.5% |
How did 300347 perform over the long term?
See historical performance and comparison